157 related articles for article (PubMed ID: 34455749)
21. Echinococcus multilocularis vesicular fluid induces the expression of immune checkpoint proteins in vitro.
Bellanger AP; Courquet S; Pallandre JR; Godet Y; Millon L
Parasite Immunol; 2020 Jun; 42(6):e12711. PubMed ID: 32171024
[TBL] [Abstract][Full Text] [Related]
22. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
Fourcade J; Sun Z; Pagliano O; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Olive D; Kuchroo V; Zarour HM
Cancer Res; 2012 Feb; 72(4):887-96. PubMed ID: 22205715
[TBL] [Abstract][Full Text] [Related]
23. [Immune Tolerance Mediated by TIM-3,LAG-3 and BTLA and Their Reversion in Hematological Malignancies-Review].
Chen SH; Zha XF; Li YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1594-1597. PubMed ID: 27784399
[TBL] [Abstract][Full Text] [Related]
24. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
25. Early transient suppression of immune checkpoint proteins T-cell immunoglobulin mucin-3 and programmed cell death-1 in peripheral blood lymphocytes after blastocyst transfer is associated with successful implantation.
Zhang T; Zhu W; Zhao Y; Cheung WC; Liu Y; Chen X; Du Y; Leung KT; Chan YL; Wang CC; Laird S; Li TC
Fertil Steril; 2020 Aug; 114(2):426-435. PubMed ID: 32199622
[TBL] [Abstract][Full Text] [Related]
26. Check point inhibitors as therapies for infectious diseases.
Cox MA; Nechanitzky R; Mak TW
Curr Opin Immunol; 2017 Oct; 48():61-67. PubMed ID: 28865357
[TBL] [Abstract][Full Text] [Related]
27. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry.
Park Y; Seo AN; Koh J; Nam SK; Kwak Y; Ahn SH; Park DJ; Kim HH; Lee HS
Oncoimmunology; 2021; 10(1):1954761. PubMed ID: 34367732
[TBL] [Abstract][Full Text] [Related]
28. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
Takamatsu K; Tanaka N; Hakozaki K; Takahashi R; Teranishi Y; Murakami T; Kufukihara R; Niwa N; Mikami S; Shinojima T; Sasaki T; Sato Y; Kume H; Ogawa S; Kakimi K; Kamatani T; Miya F; Tsunoda T; Aimono E; Nishihara H; Sawada K; Imamura T; Mizuno R; Oya M
Nat Commun; 2021 Sep; 12(1):5547. PubMed ID: 34545095
[TBL] [Abstract][Full Text] [Related]
29. PD-1 has a unique capacity to inhibit allergen-specific human CD4
Rosskopf S; Jahn-Schmid B; Schmetterer KG; Zlabinger GJ; Steinberger P
Sci Rep; 2018 Sep; 8(1):13543. PubMed ID: 30201974
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
31. T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation.
Bouvy AP; Klepper M; Kho MM; Ijzermans JN; Betjes MG; Weimar W; Baan CC
Transplantation; 2015 Sep; 99(9):1995-2003. PubMed ID: 25769075
[TBL] [Abstract][Full Text] [Related]
32. Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer.
Peng QQ; Li JL; Xin PL; Du KX; Lin XY; Wu JX; Zhang MT; Kong XQ
Neoplasma; 2021 Jul; 68(4):742-750. PubMed ID: 33847134
[TBL] [Abstract][Full Text] [Related]
33. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
34. PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients.
Al-Mterin MA; Murshed K; Elkord E
Cancer Immunol Immunother; 2023 Jun; 72(6):1933-1939. PubMed ID: 36436018
[TBL] [Abstract][Full Text] [Related]
35. Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An
Astaneh M; Rezazadeh H; Hossein-Nataj H; Shekarriz R; Zaboli E; Shabani M; Asgarian-Omran H
J Cancer Res Ther; 2022; 18(3):704-711. PubMed ID: 35900543
[TBL] [Abstract][Full Text] [Related]
36. Abnormal expression and clinical significance of surface receptors on natural killer cells in the peripheral blood of patients with non-small cell lung cancer.
Liu PC; Feng XW; Zhao XM; Ye J; He FL; Liu H; Li RM; Wang XF; Zhao DH
Neoplasma; 2022 Jul; 69(4):931-939. PubMed ID: 35652620
[TBL] [Abstract][Full Text] [Related]
37. On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.
Tundo GR; Sbardella D; Lacal PM; Graziani G; Marini S
Chemotherapy; 2019; 64(2):62-80. PubMed ID: 31387102
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer.
Kuai W; Xu X; Yan J; Zhao W; Li Y; Wang B; Yuan N; Li Z; Jia Y
Biomed Res Int; 2020; 2020():5294043. PubMed ID: 32509862
[TBL] [Abstract][Full Text] [Related]
39. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
40. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
